Detail Drug Information

desferrioxamine (desferrioxamine)

Overview of desferrioxamine

Deferoxamine is iron chelator. Deferoxamine is used in the treatment of acute iron poisoning and in conditions in which excessive iron is stored in tissues.

Indication of desferrioxamine

desferrioxamine is primarily indicated in conditions like Acute iron poisoning, Aluminium related bone disease, Aluminium -related encephalopathy, Anaemia, Blood transfusion, Chronic iron overload, Haemochromatosis, Hemochromatosis, Iron poisoning, Ocular siderosis, Transfusion-related iron overlaod.

Contraindication of desferrioxamine

deferoxamine is contraindicated in conditions like Renal impairment.

Side Effects of desferrioxamine

The severe or irreversible adverse effects of deferoxamine, which give rise to further complications include Hypotension, Hypotension.,deferoxamine produces potentially life-threatening effects which include Cardiac arrhythmia, Tachypnea, Anaphylaxis, Hypoxemia, Hypoxemia. which are responsible for the discontinuation of deferoxamine therapy.,The signs and symptoms that are produced after the acute overdosage of deferoxamine include Bradycardia, Hypotension, Loss of vision, Aphasia.,The symptomatic adverse reactions produced by deferoxamine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Redness, Allergy, Swelling, Hearing loss, Reduced visual acuity, Night blindness, Field defects, Pupillary abnormalities, Optic neuritis, Electro-oculographic abnormalities, Retinal pigmentary changes, Asymptomatic electro-retinographic abnormalities, Discomfort, Legcramps.

Precautions of desferrioxamine

Desferrioxamine should be given with caution in patients with impaired renal function.The urinary excretion of iron should be regularly monitored during treatment & periodic opthalmological (visual) & audiological (hearing) examinations are recommended for patients on long term therapy. Monitoring of cardiac function is also recommended for patients receiving combined treatment with ascorbic acid. Avoid high doses in children with low ferritin levels, because it cause the growth retardation, therefore regular checks on weight and height are recommended for children. An increased susceptibility to infection has been reported, if infectrion is suspected, treatment with desferroxamine should be stopped and should start appropriate antimicrobial treatment.